Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock is trading lower on Tuesday in reaction to Novartis AG’s (NYSE:NVS) data from the global Phase 3 HARBOR study of del-desiran for myotonic dystrophy type 1 (DM1).
Impact Of Novartis Phase 3 Trial Results
The study did not demonstrate statistically significant improvement versus placebo on the primary endpoint of video hand opening time (vHOT), a novel measure of hand myotonia. Sarepta is developing SRP-1003, an RNA-based therapy for DM1.
In 2025, the company shared progress in the Phase 1/2 multiple ascending dose (MAD) clinical study of SRP-1003 (formerly ARO-DM1).
The company expects MAD study data in the second half of 2026.
Clinical Observations And Future Dosing Regimen
In its recent earnings presentation, Sarepta noted that early data show that clinical experience to date matches preclinical data.
The company also noted no saturation of muscle siRNA uptake observed to date, with consistent dose-dependent increases in plasma and muscle drug exposures across clinical and nonclinical studies.
Enhanced siRNA chemistry improves drug stability, potentially enabling a less frequent and optimized clinical dosing regimen.
See More: Top Momentum Stocks
Sarepta Technical Analysis
Sarepta Therapeutics is currently showing a bullish setup as it trades above its key moving averages, particularly the 20-day and 50-day SMAs.
This positioning suggests that traders might be looking for a continuation of the upward trend, especially with the 20-day SMA above the 50-day SMA, indicating short-term strength.
The RSI is currently at 59.97, which is in neutral territory but close to overbought levels. This suggests that while momentum is strong, traders should be cautious of potential pullbacks if the RSI moves into overbought territory.
MACD is above its signal line, indicating bullish momentum for Sarepta Therapeutics. This positive signal suggests that the stock may continue to see upward pressure in the near term.
Key support is at 20.50, while resistance is set at 24.00. If the stock approaches the resistance level, it could signal a potential breakout, while a drop below support may indicate a reversal in trend.
Sarepta Therapeutics has not experienced a golden cross or death cross recently, which means the moving averages are not signaling a major trend change at this time.
However, the 50-day SMA is below the 200-day SMA, suggesting a bearish long-term trend that traders should keep in mind.
Looking at the 12-month performance, Sarepta Therapeutics has gained 11.16%, reflecting a positive longer-term trend despite recent volatility.
This performance indicates that, overall, the stock has been able to maintain upward momentum over the past year, which could attract longer-term investors.
SRPT Price Action: Sarepta Therapeutics shares were down 8.09% at $20.68 at the time of publication on Tuesday, according to Benzinga Pro data.
Photo: Shutterstock
Login to comment